Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Glioblastoma multiforme Clinical Trials

A listing of Glioblastoma multiforme medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (82) clinical trials

Enhancing Optune Therapy With Targeted Craniectomy

The present study proposes a new and potentially superior clinical approach to Optune™ therapy of selected glioblastoma patients. The approach is based on combining TTFields with targeted surgical skull remodeling, such as minor craniectomy or a distribution of burr holes, designed for the individual patient. Pre-clinical modeling results suggest that ...

Phase

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Gliomas account for ~80% of primary malignant tumors in the Central Nervous System (CNS), with WHO Grade IV malignant glioma (G4 MG; including glioblastoma and gliosarcoma) constituting the majority of gliomas, and are essentially incurable. Currently only surgical resection and radiotherapy (RT) with concomitant and adjuvant temozolomide (TMZ) are standard-of-care ...

Phase

A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

This is a phase I/II study of mebendazole in combination with standard of care agents for pediatric patients with gliomas. Patients with low-grade gliomas will receive a regimen of mebendazole in combination with vincristine, carboplatin, and temozolomide. Patients with high-grade gliomas and diffuse intrinsic pontine gliomas will receive a regimen ...

Phase

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

This multi-center trial is a phase 1/2 study that will be conducted in two sequential phases, phase 1 and phase 2. Phase 1 of the trial is a dose-escalation study of the safety, tolerability (MTD), and efficacy of TPI 287 in combination with bevacizumab in subjects who have GBM that ...

Phase

Phosphorus 32 in Treating Patients With Glioblastoma Multiforme

OBJECTIVES: - Determine the dosimetry toxicity of interstitial colloidal phosphorus P32 (C P32) in patients with recurrent or poor prognosis grade 4 astrocytoma. - Determine the maximum tolerated dose of C P32 administered directly into the tumor of these patients. - Determine the maximum tolerated fractionated dose of interstitial C ...

Phase

Natural History of Patients With Brain and Spinal Cord Tumors

Background: This protocol is designed to evaluate patients with tumors of the central nervous system (CNS) who appear to be probable candidates for future protocol entry or have disease manifestations that are of unique scientific interest, importance, and/or educational value. Objective: To evaluate patients with tumors of the central nervous ...

Phase N/A

Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme

OBJECTIVES: - Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib. - Determine the progression-free and overall survival of patients treated with this drug. OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed ...

Phase

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Despite recent advances, glioblastoma multiforme (GBM) remains an incurable malignancy with a short expected survival. c-MET signalling promotes invasive growth and has been described in various cancers. INC280 is a highly potent and selective c-MET inhibitor which also penetrates the blood-brain barrier. In this open-label, multicenter Phase 1b study, investigators ...

Phase

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

BACKGROUND - Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary VEGF and MMP level at the one month follow-up time point compared to the last on-treatment time point collection may be predictive of tumor recurrence at one year (l). - Note that this preliminary study included ...

Phase N/A

Safety Study of Cetuximab Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)

GERT is a one-armed single-center phase I/II trial. In a first step, dose-escalation of TMZ from 50 mg/m2 to 75mg/m2 together with radiotherapy and cetuximab will be performed. Should safety be proven, the phase II trial will be initiated with the standard dose of 75mg/m2 of TMZ. Cetuximab will be ...

Phase